Cytiva has acquired CEVEC Pharmaceuticals, a German provider of high-performance cell line development and viral vector manufacturing technologies, further strengthening Cytiva’s biomanufacturing services.
The acquisition aims to address industry challenges in cell and gene therapy in establishing production processes to keep up with the increasing demand for volume and consistent quality of viral vectors. With its scalable producer cell lines for vectors based on Adeno- Associated Virus (AAV) and Adenovirus, CEVEC covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.
